Ress Life Investments A/S: Ress Uncorrelated Assets Fund provides portfolio composition update Ress Life Investments A/S Holbergsgade 14, 2 tv DK-1057 Copenhagen K Denmark CVR nr. 33593163 www.resslifeinvestments.com To: Nasdaq Copenhagen Date: 16 September 2016
Corporate Announcement 29/2016
Ress Uncorrelated Assets Fund provides portfolio composition update
Ress Life Investments A/S acts as a feeder and invests in fund units of the master fund, Ress Uncorrelated Assets Fund. The AIF-manager of the master fund has provided the following information.
As of 31 August, the portfolio of the master fund included 206 policies with a total face value of USD 407 930 825. Below is a breakdown of the portfolio composition along different categories.
| Top Carriers | Weight% |
| John Hancock Life Insurance Company USA | 14.9% |
| AXA Equitable Life Insurance Company | 8.4% |
| Lincoln National Life Insurance Company | 8.1% |
| Transamerica Life Insurance Company | 6.2% |
| Protective Life Insurance Company | 5.9% |
| MetLife Insurance Company USA | 5.0% |
| Security Life Of Denver Insurance Company | 4.1% |
| C.M. Life Insurance Company | 3.9% |
| Lincoln Benefit Life Insurance Company | 3.8% |
| American General Life Insurance Company | 3.7% |
| Age Group | Weight% |
| <65 | 0.1% |
| 65-69 | 3.3% |
| 70-74 | 22.0% |
| 75-79 | 39.3% |
| 80-84 | 24.1% |
| 85-89 | 10.7% |
| 90-94 | 0.6% |
| Carrier Rating | Weight% |
| A++ | 6.4% |
| A+ | 70.4% |
| A | 12.6% |
| A- | 10.5% |
| Top States | Weight% |
| FL | 16.6% |
| CA | 15.8% |
| NY | 10.7% |
| TX | 5.3% |
| IL | 4.0% |
| NJ | 2.9% |
| NC | 1.9% |
| TN | 1.2% |
| WA | 0.4% |
| OK | 0.1% |
| Gender | Weight% |
| Female | 29.4% |
| Male | 70.6% |
| Mortality Rating/Multiplier | Weight% |
| <100 | 25.8% |
| 100-150 | 47.5% |
| 150-200 | 13.5% |
| 200-250 | 3.3% |
| 250-300 | 3.2% |
| 300-350 | 1.8% |
| 350-400 | 2.6% |
| 400- | 2.3% |
| BMI Group | Weight% |
| Underweight | 1.8% |
| Normal | 30.6% |
| Overweight | 37.5% |
| Obese Class I | 20.2% |
| Obese Class II | 7.4% |
| Obese Class III | 2.5% |
| Blood pressure | Weight% |
| Hypotension | 7.6% |
| Normal | 15.2% |
| Prehypertension | 52.1% |
| Stage 1 Hypertension | 21.5% |
| Stage 2 Hypertension | 3.5% |
| Life Expectancy | Weight% |
| < 2 | 0.1% |
| 2-3 | 0.6% |
| 4-5 | 2.5% |
| 6-7 | 9.1% |
| 8-9 | 20.8% |
| 10-11 | 33.2% |
| 12-15 | 22.3% |
| 16- | 11.5% |
| Impairment Category | Weight% |
| Endocrine/Metabolic | 21.5% |
| Gastro Intestinal | 14.2% |
| Cardiac | 13.6% |
| Musculoskeletal | 10.8% |
| Genito-Urinary | 5.9% |
| Dermatologic Cond. | 5.6% |
| ENT | 5.3% |
| Ophthalmologic Diseases | 4.4% |
| Pulmonary | 4.3% |
| Hematology | 3.0% |
| Psychiatric Disorders | 2.7% |
| Renal | 1.8% |
| Oncology | 1.7% |
| Cerebro-Vascular | 1.6% |
| Neurology | 1.2% |
| Vascular Disorders | 0.7% |
| Infectious Disease | 0.7% |
| Miscellaneous | 0.5% |
| Gynecological Cond. | 0.3% |
| Psychiatric | 0.2% |
| Rheumatologic/Immuno | 0.1% |
| Category | Sub-category breakdown | Weight% |
| Endocrine/Metabolic | Dyslipidemia -- Lipid Profile | 12.7% |
| Cardiac | Hypertension(HTN) -- Controlled HTN | 8.7% |
| Endocrine/Metabolic | Diabetes Mellitus -- Type 2 Diabetes Mellitus | 4.6% |
| Musculoskeletal | Bone Density -- Osteopenia | 3.8% |
| Ophthalmologic Diseases | Cataracts | 3.5% |
| Endocrine/Metabolic | Thyroid Disease -- Hypothyroidism | 3.3% |
| Gastro Intestinal | Polyps -- Colon polyps | 2.6% |
| Genito-Urinary | ED | 2.3% |
| Dermatologic Cond. | Squamous Cell Carcinoma | 2.2% |
| Dermatologic Cond. | Keratosis -- Actinic Keratosis | 2.1% |
| Cardiac | Atrial Fibrillation -- A-Fib Considered | 1.8% |
| Psychiatric Disorders | Depression -- Depression (Mild/Unspecified) | 1.8% |
| ENT | Allergy -- Allergic rhinitis | 1.6% |
| Gastro Intestinal | Hemorrhoids -- Internal Hemorrhoids | 1.3% |
| Pulmonary | Sleep Apnea | 1.3% |
| Ophthalmologic Diseases | Glaucoma | 0.9% |
| Endocrine/Metabolic | Gout | 0.8% |
| Oncology | Prostate Cancer -- Grade 2: Gleason 5-7 | 0.6% |
| Gastro Intestinal | Liver -- Fatty Liver | 0.6% |
| Cerebro-Vascular | Carotid Disease | 0.5% |
| Cerebro-Vascular | Stroke/CVA | 0.5% |
| ENT | Ear Disorders (Vestibulo-Cochlear) | 0.4% |
| Pulmonary | URI | 0.4% |
| Gastro Intestinal | Ulcerative Colitis | 0.1% |
| Gastro Intestinal | GERD -- Mild GERD | 0.1% |
| Pulmonary | COPD -- Symptoms of COPD | 0.1% |
| Oncology | Colon/Rectal Cancer | 0.1% |
| Rheumatologic/Immuno | Rheumatoid Arthritis | 0.1% |
| Ophthalmologic Diseases | Macular Degeneration | 0.1% |
| Gastro Intestinal | Polyps -- Polypectomy | 0.1% |
Questions related to this announcement can be made to the company's AIF-manager, Resscapital AB.
Contact person: Jonas Mårtenson jonas.martenson@resscapital.com Tel + 46 8 545 282 09
